Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine

References

• World Health Organisation. Global policy report on the prevention and control of viral hepatitis in WHO member states. [cited 22 April 2016]; Available from: http://apps.who.int/iris/bitstream/10665/85397/1/9789241564632_eng.pdf?ua=1
   Google Scholar
• Global Burden of Disease Pediatrics Collaboration, Kyu HH, Pinho C, Wagner JA, Brown JC, Bertozzi-Villa A, Charlson FJ, Coffeng LE, Dandona L, Erskine HE, Ferrari AJ, et al. Global and national burden of diseases and injuries among children and adolescents between 1990 and 2013: Findings from the Global Burden of Disease 2013 study. JAMA Pediatr 2016; 170:267-87; PMID:26810619; http://dx.doi.org/10.1001/jamapediatrics.2015.4276
   PubMed Web of Science ®Google Scholar
• Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, Coppola N. Hepatitis B virus burden in developing countries. World J Gastroenterol 2015; 21:11941-53; PMID:26576083; http://dx.doi.org/10.3748/wjg.v21.i42.11941
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Prevention and Control of Viral Hepatitis Infection: Framework for Global Action. Available at: http://apps.who.int/iris/bitstream/10665/130012/1/WHO_HSE_PED_HIP_GHP_2012.1_eng.pdf?ua=1&ua=1; accessed 22 April 2016
   Google Scholar
• Locarnini S, Hatzakis A, Chen DS, Lok A. Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. J Hepatol 2015; 62(1 Suppl):S76-86; PMID:25920093; http://dx.doi.org/10.1016/j.jhep.2015.01.018
   PubMed Web of Science ®Google Scholar
• Martinez A, Broner S, Sala MR, Manzanares-Laya S, Godoy P, Planas C, Minguell S, Torner N, Jané M, Domínguez A, et al. Changes in the epidemiology of hepatitis A outbreaks 13 years after the introduction of a mass vaccination program. Hum Vaccin Immunother 2015; 11:192-7; PMID:25483535; http://dx.doi.org/10.4161/hv.35861
   PubMed Web of Science ®Google Scholar
• Van Herck K, Van Damme P. Prevention of hepatitis A by Havrix: a review. Expert Rev Vaccines 2005; 4:459-71; PMID:16117704; http://dx.doi.org/10.1586/14760584.4.4.459
   PubMed Web of Science ®Google Scholar
• Van Damme P, Mathei C, Thoelen S, Meheus A, Safary A, Andre FE. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J Med Virol 1994; 44:435-41; PMID:7897376; http://dx.doi.org/10.1002/jmv.1890440422
   PubMed Web of Science ®Google Scholar
• Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: A historical overview. Vaccine 2008; 26:6266-73; PMID:18848855; http://dx.doi.org/10.1016/j.vaccine.2008.09.056
   PubMed Web of Science ®Google Scholar
• Theeten H, Van Herck K, Van Der Meeren O, Crasta P, Van Damme P, Hens N. Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine 2015; 33:5723-7; PMID:26190091; http://dx.doi.org/10.1016/j.vaccine.2015.07.008
   PubMed Web of Science ®Google Scholar
• Gilca V, De Serres G, Boulianne N, Murphy D, Ouakki M, De Wals P, Trudeau G, Massé R, Dionne M. Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine. Hum Vaccin Immunother 2013; 9:1685-90; PMID:23744506; http://dx.doi.org/10.4161/hv.25015
   PubMed Web of Science ®Google Scholar
• Poovorawan Y, Chongsrisawat V, Theamboonlers A, Crasta PD, Messier M, Hardt K. Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: a 20-year follow-up study in Thailand. Hum Vaccin Immunother 2013; 9:1679-84; PMID:23732904; http://dx.doi.org/10.4161/hv.24844
   PubMed Web of Science ®Google Scholar
• Van Damme P. Long-term protection after hepatitis B vaccine. J Infect Dis 2016; 214:1-3; PMID:26802140; http://dx.doi.org/10.1093/infdis/jiv750
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17:1055-65; PMID:20463105; http://dx.doi.org/10.1128/CVI.00131-10
   PubMed Web of Science ®Google Scholar
• Chiara F, Bartolucci GB, Cattai M, Piazza A, Nicolli A, Buja A, Trevisan A. Hepatitis B vaccination of adolescents: Significance of non-protective antibodies. Vaccine 2014; 32:62-8; http://dx.doi.org/10.1016/j.vaccine.2013.10.074
   Web of Science ®Google Scholar
• Thoelen S, Van Damme P, Leentvaar-Kuypers A, Leroux-Roels G, Bruguera M, Frei PC, Bakasenas V, Safary A. The first combined vaccine against hepatitis A and B: an overview. Vaccine 1999; 17:1657-62; PMID:10194819; http://dx.doi.org/10.1016/S0264-410X(98)00421-6
   PubMed Web of Science ®Google Scholar
• Bakker M, Bunge EM, Marano C, de Ridder M, De Moerlooze L. Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review. Expert Rev Vaccines 2016; 15:829-51; PMID:26840060; http://dx.doi.org/10.1586/14760584.2016.1150182
   PubMed Web of Science ®Google Scholar
• Thoelen S, Van Damme P, Beutels M, Mathei C, Meheus A. Immunogenicity of a combined hepatitis A and hepatitis B vaccine in healthy adults. Hepatol 1996; 23:254
   Web of Science ®Google Scholar
• Leroux-Roels G, Moreau W, Desombere I, Safary A. Safety and immunogenicity of a combined hepatitis A and hepatitis B vaccine in young healthy adults. Scand J Gastroenterol 1996; 31:1027-31; PMID:8898425; http://dx.doi.org/10.3109/00365529609003124
   PubMed Web of Science ®Google Scholar
• Van Damme P, Leroux-Roels G, Law B, Diaz-Mitoma F, Desombere I, Collard F, Tornieporth N, Van Herck K. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol 2001; 65:6-13; PMID:11505437; http://dx.doi.org/10.1002/jmv.1094
   PubMed Web of Science ®Google Scholar
• Van Herck K, Leroux-Roels G, Van Damme P, Srinivasa K, Hoet B. Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults. Travel Med Infect Dis 2007; 5:171-5; PMID:17448944; http://dx.doi.org/10.1016/j.tmaid.2006.07.003
   PubMedGoogle Scholar
• Van Damme P, Leroux-Roels G, Crasta P, Messier M, Jacquet JM, Van Herck K. Antibody persistence and immune memory in adults, 15 years after a 3-dose schedule of a combined hepatitis A and B vaccine. J Med Virol 2012; 84:11-7; PMID:22052690; http://dx.doi.org/10.1002/jmv.22264
   PubMed Web of Science ®Google Scholar
• Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 2001; 63:1-7; PMID:11130881; http://dx.doi.org/10.1002/1096-9071(200101)63:1%3c1::AID-JMV1000%3e3.0.CO;2-U
   PubMed Web of Science ®Google Scholar
• Wiedermann G, Kundi M, Ambrosch F, Safary A, D'Hondt E, Delem A. Inactivated hepatitis A vaccine: long-term antibody persistence. Vaccine 1997; 15:612-15; PMID:9178459; http://dx.doi.org/10.1016/S0264-410X(96)00242-3
   PubMed Web of Science ®Google Scholar
• Ott JJ, Irving G, Wiersma ST. Long-term protective effects of hepatitis A vaccines. A systematic review. Vaccine 2012; 31:3-11
   PubMed Web of Science ®Google Scholar
• Van Der Meeren O, Behre U, Crasta P. Immunity to hepatitis B persists in adolescents 15–16 years of age vaccinated in infancy with 3 doses of hepatitis B vaccine. Vaccine 2016; 34:2745-9; PMID:27095043; http://dx.doi.org/10.1016/j.vaccine.2016.04.013
   PubMed Web of Science ®Google Scholar
• Beran J, Van Der Meeren O, Leyssen M, D'silva P. Immunity to hepatitis A and B persists for at least 15 years after immunisation of adolescents with a combined hepatitis A and B vaccine. Vaccine 2016; 34:2686-91; PMID:27105563; http://dx.doi.org/10.1016/j.vaccine.2016.04.033
   PubMed Web of Science ®Google Scholar
• Steiner M, Ramakrishnan G, Gartner B, Van Der Meeren O, Jacquet JM, Schuster V. Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life. BMC Infect Dis 2010; 10:9; PMID:20078876; http://dx.doi.org/10.1186/1471-2334-10-9
   PubMed Web of Science ®Google Scholar
• Avdicova M, Crasta PD, Hardt K, Kovac M. Lasting immune memory against hepatitis B following challenge 10–11 years after primary vaccination with either 3 doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11–12 months of age. Vaccine 2015; 33:2727-33; PMID:24962750; http://dx.doi.org/10.1016/j.vaccine.2014.06.070
   PubMed Web of Science ®Google Scholar
• Hens N, Ghebretinsae AH, Hardt K, Van Damme P, Van Herck K. Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. Vaccine 2014; 32:1507-13; PMID:24508042; http://dx.doi.org/10.1016/j.vaccine.2013.10.088
   PubMed Web of Science ®Google Scholar